Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Emery

Showing results (101-110 of 140) with videos related to

Pageof 14
Sort By:
AIDS (London, England)|March 3, 2006
A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1Anthony D Kelleher, Rebekah L Puls, Mark Bebbington, et al.
The Journal of Infectious Diseases|May 14, 2008
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study, Sean Emery, Jacqueline A Neuhaus, et al.
Antimicrobial Agents and Chemotherapy|December 21, 2011
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 studyLaura J Else, Akil Jackson, Rebekah Puls, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 16, 2014
Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trialAlan Winston, Janaki Amin, Amanda Clarke, et al.
The Journal of Infectious Diseases|September 21, 2011
Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trialHelen Byakwaga, Mark Kelly, Damian F J Purcell, et al.
AIDS Research and Human Retroviruses|June 28, 2016
Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE StudyEdward P Lam, Cecilia L Moore, Eduardo Gotuzzo, et al.
The Lancet. Infectious Diseases|March 14, 2013
The search for an HIV cure: tackling latent infectionStephen J Kent, Jeanette C Reece, Janka Petravic, et al.
Open Forum Infectious Diseases|January 9, 2018
Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009-2015Dominic E Dwyer, Ruth Lynfield, Marcelo H Losso, et al.
Plos Clinical Trials|July 28, 2006
A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard StudyMike Youle, Sean Emery, Martin Fisher, et al.
Open Forum Infectious Diseases|January 9, 2018
Systemic Inflammation, Coagulation, and Clinical Risk in the START TrialJason V Baker, Shweta Sharma, Birgit Grund, et al.
Pageof 14

Showing results (101-110 of 140) with videos related to

Sort By:
Pageof 14
AIDS (London, England)|March 3, 2006
A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1Anthony D Kelleher, Rebekah L Puls, Mark Bebbington, et al.
The Journal of Infectious Diseases|May 14, 2008
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study, Sean Emery, Jacqueline A Neuhaus, et al.
Antimicrobial Agents and Chemotherapy|December 21, 2011
Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 studyLaura J Else, Akil Jackson, Rebekah Puls, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 16, 2014
Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trialAlan Winston, Janaki Amin, Amanda Clarke, et al.
The Journal of Infectious Diseases|September 21, 2011
Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trialHelen Byakwaga, Mark Kelly, Damian F J Purcell, et al.
AIDS Research and Human Retroviruses|June 28, 2016
Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE StudyEdward P Lam, Cecilia L Moore, Eduardo Gotuzzo, et al.
The Lancet. Infectious Diseases|March 14, 2013
The search for an HIV cure: tackling latent infectionStephen J Kent, Jeanette C Reece, Janka Petravic, et al.
Open Forum Infectious Diseases|January 9, 2018
Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009-2015Dominic E Dwyer, Ruth Lynfield, Marcelo H Losso, et al.
Plos Clinical Trials|July 28, 2006
A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard StudyMike Youle, Sean Emery, Martin Fisher, et al.
Open Forum Infectious Diseases|January 9, 2018
Systemic Inflammation, Coagulation, and Clinical Risk in the START TrialJason V Baker, Shweta Sharma, Birgit Grund, et al.
Pageof 14